NEW YORK, May 22, 2026, 13:08 (ET)
Privia Health Group shares edged higher in midday trading on Friday after the company posted annual-meeting results, a routine filing that left investors focused on whether its first-quarter growth can carry through the rest of 2026. PRVA was recently around $22.78, up about 0.6%, while Wall Street broadly gained ahead of the Memorial Day weekend; Nasdaq lists Monday, May 25, as a market holiday.
The stock’s move was small because the filing did not change the operating story. It matters now because Privia is being judged more on its value-based care business — contracts where doctors and care networks can be paid for keeping costs down and outcomes up, not just for each visit — than on Friday’s governance update.
Privia said shareholders approved all three proposals at its May 20 annual meeting: re-election of Nancy Cocozza, David King and Francis Soistman as Class I directors, an advisory vote on executive pay, and ratification of PricewaterhouseCoopers as auditor for 2026.
A separate Form 4 filed Friday showed Cocozza received 8,463 restricted stock units at $0, an annual equity grant rather than an open-market buy. The units vest on the earlier of the day before the 2027 annual meeting or the first anniversary of the grant date.
The operating backdrop is more material. Privia reported May 7 that first-quarter revenue rose 25.8% to $603.8 million, while net income attributable to the company fell to $3.1 million from $4.2 million. Adjusted EBITDA — earnings before interest, taxes, depreciation and amortization, with some items stripped out — rose 36.3% to $36.7 million. Practice collections, the total money collected through its practices and reimbursement sources, rose 14.6% to $914.8 million.
The company kept its 2026 revenue outlook at $2.35 billion to $2.45 billion and adjusted EBITDA guidance at $145 million to $155 million. It raised its forecast for attributed lives, or patients assigned to Privia under value-based arrangements, to 1.60 million to 1.625 million, and said it expects about 80% of adjusted EBITDA to convert to free cash flow, cash left after operating needs and capital spending.
On the May 7 call, Chief Executive Parth Mehrotra told analysts it was “still early in the year” and said Privia’s approach was to “keep executing every quarter” before changing most guidance. Chief Financial Officer David Mountcastle pointed to a “robust pipeline” of existing-market expansion and new-market opportunities, though the formal outlook assumes no new business development.
Mehrotra also pushed back against a simple all-or-nothing view of Medicare Advantage risk, saying “full capitation is not the only way to perform well.” Capitation means providers receive a fixed amount per patient, which can lift returns if costs are controlled but can hurt if medical costs run hot.
Competition is close enough to matter. agilon Health also sells investors on a physician-partner model built around the “value of care, not the volume of fees,” while Astrana Health describes itself as a physician-centric, technology-powered, risk-bearing healthcare management company. For Privia, the point is whether provider growth and patient attribution can scale without importing too much insurer-like medical-cost volatility. agilon health
But the downside case is not hard to sketch. The company itself flags risks from healthcare regulation, the legal complexity of medical-group relationships, competition, reimbursement pressure, vendor disruptions and privacy or cybersecurity issues; any of those could blunt the margin gains investors are trying to underwrite.
For now, PRVA is a stock with a quiet governance update, a small midday gain and a bigger question still open: whether the raised lives target turns into cash, not just scale.
